Table 2.

Clinical outcomes between notification and control groups

	Notification group (n = 150)	Control group (n = 150)	P value
MRSA nasal colonization (%)	13 (8.66)	14 (9.33)	0.84
Duration of anti-MRSA (days) (±S)	5.66 ± 3.75	7.87 ± 4.84	<0.001
Hospitalization costs ($)[M (P_25, P₇₅)]	10772.14 (5970.76, 21934.47)	14652.57 (7772.53,28,442.47)	0.061
Antibiotic costs ($)[M (P_25, P₇₅)]	621.78 (323.15, 1309.40)	881.70 (416.93, 2324.73)	0.013
Hospital length of stay (days) (±S)	18.13 ± 12.42	22.63 ± 19.07	0.179
ICU length of stay (days) (±S)	8.88 ± 10.29	10.50 ± 11.15	0.270
In-hospital mortality (%)	19(12.67)	25(16.67)	0.327
Thrombocytopenia (%)	1 (0.67)	5 (3.33)	0.214
New bacteria (%)	22 (14.67)	34 (22.67)	0.075
Enter ICU (%)	2 (1.33)	4 (2.67)	0.684
Antibiotic associated diarrhea (%)	3 (2.00)	8 (5.33)	0.281
Renal function damage (%)	0 (0.00)	7 (4.67)	0.015
Liver function damage (%)	2 (1.33)	12 (8.00)	0.006